首页> Liver international : official journal of the International Association for the Study of the Liver> Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.

导出原文传递

翻译打印收藏纠错

第一作者： Eric,Lawitz

第一单位： The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA.

作者： Eric,Lawitz ^[1] ; Robert,Flisiak ^[2] ; Manal,Abunimeh ^[3] ; Meghan E,Sise ^[4] ; Jun Y,Park ^[5] ; Marwan,Kaskas ^[6] ; Annette,Bruchfeld ^[7] ; Marcus-Alexander,Wörns ^[8] ; Andrea,Aglitti ^[9] ; Philippe J,Zamor ^[10] ; Zhenyi,Xue ^[3] ; Gretja,Schnell ^[3] ; Yash J,Jalundhwala ^[3] ; Ariel,Porcalla ^[3] ; Federico J,Mensa ^[3] ; Marcello,Persico ^[9]

作者单位： The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA. ^[1] Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. ^[2] AbbVie, Inc., North Chicago, IL, USA. ^[3] Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA. ^[4] Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. ^[5] Northwest Louisiana Nephrology, Shreveport, LA, USA. ^[6] Department of Renal Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. ^[7] Department of Internal Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. ^[8] Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy. ^[9] Carolinas Medical Center, Charlotte, NC, USA. ^[10]

关键词 chronic kidney disease cirrhosis direct-acting antiviral hepatitis C virus pangenotypic